Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer

Cancer Investigation

Volumn 14, Issue 6, 1996, Pages 513-517

  Figg, William D ^a,d   Ammerman, Kara ^a   Patronas, Nicholas ^a   Steinberg, Seth M ^a   Walls, Ronald G ^a   Dawson, Nancy ^a,b   Reed, Eddie ^a   Sartor, Oliver ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c LA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; SOFT TISSUE;

EID: 0030459521     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609076896     Document Type: Article

References (12)

1. Huggins C, Hodges CV: Studies on prostate cancer. I. The effect of castration of estrogen and of androgen injection on serum phosphatascs in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.
2. Scher HI, Curley T, Yeh S, et al: Therapeutic alternatives for hormone-refractory prostate cancer. Semin Urol 10:55-64, 1992.
3. Hanks GE, Myers CE, Scardino PT: Cancer of the prostate. In: Cancer: Principles and Practice of Oncology, 4th ed, edited by VT Devita, S Hollman, SA Rosenberg. Philadelphia, Lippincott, 1993.
4. Oesterling JE, Martin SK, Bergstralh EJ, et al: The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269:57-60, 1993.
5. Pantelides ML, Bowman SP, George NJ: Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol 70:299-303, 1992.
6. Oesterling JE: Using PSA to eliminate the staging radionuclide bone scan: Significant economic implications. Urol Clin North Am 20:705-711, 1993.
7. Platt JF, Bree RL, Schwab RE: The accuracy of CT in the staging of carcinoma of the prostate. Am J Roentgenol 149:315-318, 1987.
8. Bluestein DL, Bostwick DG, Bergstralh EJ, et al: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 151:1315-1320, 1994.
9. Narayan P, Fournier G, Gajendran V, et al: Utility of preoperative serum prostate-specific antigen concentration and biospy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 44:519-524, 1994.
10. Sanders H, Smith E, Woodward M, et al. The use of PSA to predict bone metastases in recurrence after definitive local therapy for prostate cancer. Proc Am Urol Assoc 153:238A, 1995 (abstract).
11. Luke MC, Coffey DS: Human androgen receptor binding to the androgen response clement of prostate specific antigen. J Androl 15:41-51, 1994.
12. Gulfo J: Clinical utility of monoclonal antibodies in prostate cancer. In: Prostate Cancer, edited by NA Dawson, NJ Vogelzang. New York, Wiley-Liss, 1994.